Study Comparing Myofascial Trigger Point Injection and Greater Occipital Nerve Block for Treating Chronic Migraine in Adults Aged 18 to 65

What this Trial Is About

Chronic migraine is a widespread condition in China, especially among older adults, significantly affecting quality of life. This research evaluates and compares two injection treatments glucocorticoid injections at myofascial trigger points and greater occipital nerve block injections. The study is a prospective, randomized, controlled, and blinded trial designed to see if the trigger point injection is at least as effective as the nerve block for managing chronic migraine over the long term. Participants are randomly assigned to one of two groups. One group receives injections of triamcinolone acetonide combined with lidocaine at identified myofascial trigger points using a 25-gauge needle. The other group undergoes ultrasound-guided bilateral greater occipital nerve block injections with triamcinolone acetonide and lidocaine. Treatment is administered as a single bolus per injection site, and patients are followed for two years to monitor outcomes. During the study, patients will be regularly assessed at 2, 4, 8, 12, and 24 weeks after treatment for pain intensity using the Numerical Rating Scale NRS, frequency and duration of migraine attacks, Patient Global Impression of Change PGIC, and any adverse reactions. Safety and efficacy data will be collected throughout the study, with a focus on 4-week NRS pain scores as the primary outcome. This thorough monitoring helps understand how well each injection approach manages chronic migraine over time.

Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Migraine